Sandra Leung - Bristol Myers Executive Vice President, General Counsel

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

Fiscal Quarter End: 30th of June 2020  

  President
Ms. Sandra Leung serves as Executive Vice President, General Counsel of the Company. From 2007 to 2014 General Counsel and Corporationrationrate Secretary, 2014 to 2015 Executive Vice President, General Counsel and Corporationrationrate Secretary, 2015 to present Executive Vice President, General Counsel.
Age: 58  President Since 2015      
212 546-4020  www.bms.com

Sandra Leung Latest Insider Activity

Bristol Myers Management Efficiency

Bristol Myers Squibb has Return on Asset of 7.0E-4 % which means that on every $100 spent on asset it made $7.0E-4 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.0017 % implying that it generated $0.0017 on every 100 dollars invested. Bristol Myers management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Return on Investment is likely to grow to 15.40 in 2020. Return on Average Assets is likely to grow to 0.07 in 2020Bristol Myers Assets Non Current are fairly stable at the moment as compared to the last year. Bristol Myers reported Assets Non Current of 100.59 Billion in 2019. Goodwill and Intangible Assets is likely to grow to about 93.3 B in 2020, whereas Total Assets are likely to drop slightly above 31.7 B in 2020. Bristol Myers Total Liabilities is fairly stable at the moment as compared to the last year. Bristol Myers reported Total Liabilities of 78.25 Billion in 2019. Liabilities Non Current is likely to grow to about 64.7 B in 2020, whereas Current Liabilities is likely to drop slightly above 8 B in 2020.
The company has 25.8 B in debt with debt to equity (D/E) ratio of 159.7 . This implies that the company may be unable to create cash to meet all of its financial commitments. Bristol Myers Squibb has Current Ratio of 3.8 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Katie WatsonGilead Sciences
N/A
Regis SimardGlaxoSmithKline PLC
2018
Pam ChengAstrazeneca PLC
2015
David FredricksonAstrazeneca PLC
2017
Jim ScholefieldMerck Company
2018
Mark MallonAstrazeneca PLC
2016
Julie GerberdingMerck Company
2016
Frank ClyburnMerck Company
2019
Luke MielsGlaxoSmithKline PLC
2017
Sanat ChattopadhyayMerck Company
2016
Lafmin MorganGrifols S A
N/A
Jeffrey SimmonsEli Lilly And
2008
Adele AmbroseMerck Company
2009
Christi ShawEli Lilly And
2017
Sean BohenAstrazeneca PLC
2015
Robert DavisMerck Company
2016
Anne WhiteEli Lilly And
2018
James BradnerNovartis AG
2016
Willie DeeseMerck Company
N/A
Enrique ConternoEli Lilly And
2017
Kathleen WatsonGilead Sciences
N/A

Company Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 30000 people.Bristol Myers Squibb (BMY) is traded on BATS Exchange in USA. It is located in 430 E. 29th Street 14th Floor, New York, NY 10016, United States and employs 30,000 people. Bristol Myers is listed under Pharmaceutical Products category by Fama And French industry classification.

Bristol Myers Squibb Leadership Team

Ann Powell, Chief Human Resource Officer, Senior Vice President
Togo West, Independent Director
Karen Vousden, Independent Director
Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics Officer
Michael Bonney, Independent Director
Alan Lacy, Independent Director
Robert Bertolini, Independent Director
Jose Baselga, Independent Director
Charles Bancroft, Chief Financial Officer, Executive Vice President - Global Business Operations
Gerald Storch, Independent Director
Louis Schmukler, Executive Vice President, President - Global Product Development and Supply
Michael Grobstein, Independent Director
Christopher Boerner, Executive Vice President and Chief Commercial Officer
Phyllis Yale, Independent Director
John Elicker, Senior Vice President - Corporate Affairs and Investor Relations
David Elkins, Executive Vice President and Chief Financial Officer Member of the Leadership Team
Anne Nielsen, Senior Vice President Chief Compliance and Ethics Officer
Karen Santiago, Senior Vice President, Corporate Controller
Rupert Vessey, Executive Vice President Research and Early Development Member of the Leadership Team
Giovanni Caforio, Chairman of the Board, Chief Executive Officer
Vicki Sato, Lead Independent Director
Emmanuel Blin, Senior Vice President Chief Strategy Officer
Nadim Ahmed, Executive Vice President and President - Hematology
Joseph Caldarella, Senior Vice President Corporate Controller
Julia Haller, Independent Director
Laurie Glimcher, Independent Director
Murdo Gordon, Executive Vice President Chief Commercial Officer
Lamberto Andreotti, Executive Chairman, Officer, Ex-Officio Member of Audit Committee, Ex-Officio Member of Committee on Directors and Corporate Governance and Ex-Officio Member of Compensation and Management Devel. Committee
Joseph Eid, Senior Vice President and Head of Global Medical Affairs Member of the Leadership Team
Thomas Lynch, Chief Scientific Officer, Executive Vice President
Lewis Campbell, Independent Director
Dinesh Paliwal, Independent Director
Theodore Samuels, Independent Director
Samuel Moed, Senior Vice President - Strategic Planning and Analysis
Matthew Emmens, Independent Director
Ann Judge, Chief Human Resource Officer, Senior Vice President Member of the Leadership Team
Sandra Leung, Executive Vice President, General Counsel
Paul Autenried, Chief Information Officer, Senior Vice President
Samit Hirawat, Executive Vice President Chief Medical Officer, Global Drug Development Member of the Leadership Team
Tim Power, Vice President of Investor Relations
Francis Cuss, Executive Vice President Chief Scientific Officer
Paul Biondi, Senior Vice President, Head of Strategy & Business Development
Kathryn Metcalfe, Executive Vice President - Corporate Affairs Member of the Leadership Team
Peter Arduini, Independent Director
Elizabeth Mily, Executive Vice President - Strategy & Business Development

Stock Performance Indicators

Current Sentiment - BMY

Bristol Myers Squibb Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Bristol Myers Squibb. What is your opinion about investing in Bristol Myers Squibb? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Bristol Myers Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Bristol Myers and Astrazeneca PLC. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Trending Equities. Please also try Bollinger Bands module to use bollinger bands indicator to analyze target price for a given investing horizon.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page